Skip to content
MARKETS / NASDAQ / INMD
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

InMode Ltd. INMD

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$370.5M
▼ 6.2% YoY
$93.8M
▼ 48.2% YoY
$84.3M
▼ 36.1% YoY
Growth
USD 370.5M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 370.5 · Net income 93.8
200M400M201720182019202020212022202320242025
Compound annual growth
−6.6%
+12.4%
−16.6%
−8.9%
+9.9%
+45.3%
+58.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
25 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 23.0% · Net 25.3%
20%40%201720182019202020212022202320242025
ROE
FY2025 · ROE 13.5%
20%40%201720182019202020212022202320242025

Each USD of equity produced 14 cents of profit this year.

Cash & shareholders
USD 126.1M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 84.3
80M160M201720182019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 126.1
100M200M202020212022202320242025

USD 126.1M in buybacks — 134% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 766.4M
EquityUSD 683.2M
CashUSD 302.5M
Current ratio9.88×

Equity funds 89% of total assets.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.40.40.50.50.40.20.20.10.1
Operating income $B0.10.10.20.20.20.10.10.00.0
EBITDA $B0.10.10.20.20.20.10.10.00.0
Income tax $B0.0−0.00.00.00.00.00.00.00.0
Net income $B0.10.20.20.20.20.10.10.00.0
Free cash flow $B0.10.10.20.20.20.10.10.00.0
EPS, diluted $1.432.252.301.891.920.890.800.620.26
Dividend / sh $·········
Payout %·········
ROE %13.524.329.533.349.334.955.851.7·
Shares out B0.060.070.080.080.080.080.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 2 divergences in 43 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures2 divergent
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image